Anthem Biosciences Sees ₹1,275 Crore Block Deal as Societe Generale, Prudential Buy 3% Stake 

Anthem Biosciences just attracted serious global institutional attention. On June 19, 2026, the Bengaluru-based pharma services company saw a large block deal hit the National Stock Exchange. Global investors led by Societe Generale, Prudential Hong Kong, and Ghisallo Capital Management acquired a combined 3% stake in Anthem Biosciences from promoter Aruna Ganesh for ₹1,275 crore through open market transactions. 

HDFC MF, SBI MF among buyers in Anthem Biosciences as promoter group entity offloads 3.05% stake

Read More:https://t.co/6bGPoPCMyk

— Moneycontrol (@moneycontrolcom) June 18, 2026

Following the transaction, combined promoter and promoter group holding declined to 71.63% from 74.68%.The deal marks one of the largest promoter stake sales in India’s pharma services sector this year, with investors closely monitoring its impact despite a largely measured market response.

Inside the ₹1,275 Crore Block Deal

The scale and structure of this deal reveal genuine institutional conviction in Anthem Biosciences. The transaction also drew participation from several domestic mutual funds, insurance companies, and an investment firm, according to block deal data published on the NSE. 

Here are the core deal metrics:

• Total deal value: ₹1,275 crore
• Stake acquired: Approximately 3% (3.1% per some reports)
• Seller: Promoter Aruna Ganesh
• Lead buyers: Societe Generale, Prudential Hong Kong, Ghisallo Capital Management
• Domestic participants included SBI Mutual Fund, HDFC Mutual Fund, and Kotak Mahindra Mutual Fund
• Promoter holding post-deal: 71.63%, down from 74.68%

The block deal data confirms an equity stake of approximately 3.1% in Anthem Biosciences, worth Rs 1,275 crore, reportedly changed hands during the session.

Anthem Biosciences Stock: How Shares Reacted

The market’s response to the block deal was notably volatile within the same trading session. Shares of Anthem Biosciences declined as much as 0.88% to hit an intraday low of ₹791.05 during the noon session, after opening in the red and surging as much as 2.09% to reach a session peak of ₹814.80 in early deals.

Key stock data points as of June 19, 2026:

• Trading price (around 12:24 PM): ₹794.40, down 0.46%
• Intraday high: ₹814.80
• Intraday low: ₹791.05
• Earlier session reading: Up 3.80% at ₹796.65, per a separate intraday update
• 52-week high: ₹873.50, set September 19, 2025
• 52-week low: ₹579.15, touched February 2, 2026
• Market capitalisation as of June 19, 2026 stood at ₹44,765.56 crore 

The stock has gained nearly 1% over the past month and 24% on a year-to-date basis. 

Why Institutional Buyers Are Betting on Anthem Biosciences

Anthem Biosciences operates in one of India’s fastest-growing pharma sub-sectors, and that backdrop helps explain the institutional appetite. Founded in 2006 and based in Bengaluru, Anthem Biosciences operates as a Contract Research, Development and Manufacturing Organization, providing services spanning small molecules, large molecules, peptides, lipids, oligonucleotides, and antibody-drug conjugates. 

A Debt-Free Balance Sheet and Dividend Boost

Anthem Biosciences has maintained a largely debt-free balance sheet, giving it flexibility to fund expansion projects without heavy interest payment burdens a meaningful advantage in a capital-intensive CRDMO industry. A dividend announcement adds further near-term relevance: Anthem Biosciences has announced a dividend of Rs 2 per share, with an ex-date of June 25, 2026. For income-focused investors, this timing aligns with the stock’s renewed institutional spotlight.

Conclusion

The ₹1,275 crore Anthem Biosciences block deal on June 19, 2026, signals strong global confidence in India’s pharma services sector. With Societe Generale, Prudential Hong Kong, and Ghisallo Capital Management stepping in as a promoter exits part of their stake, the transaction reflects a broader institutional rotation into CRDMO names. With shares up 24% year-to-date and a market cap near ₹44,766 crore, Anthem Biosciences remains one of the most closely watched recent listings in Indian pharma.

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.